Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Summary

The purpose of this pre-approval access program is to give talquetamab monotherapy (treatment with single drug) to participants with relapsed or refractory multiple myeloma (a type of cancer that begins in plasma cells \[white blood cells that produce antibodies\] which has returned or difficult to treat) who have relapsed on or are refractory to all locally available and clinically appropriate treatment and who are not eligible for a clinical trial.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications